Global Information
회사소개 | 문의 | 위시리스트

의약품 리더 시리즈 : 의약품 위탁생산기관(CMO) 시장의 상위 50사(2018년) : 재무 실적, 서비스, 생산능력, 기업인수합병(M&A), SWOT 분석

Pharma Leader Series: Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market 2018: Financial Performances, Services, Capacities, Mergers & Acquisitions, SWOT Analysis

리서치사 Visiongain Ltd
발행일 2018년 09월 상품 코드 274875
페이지 정보 영문 257 Pages
가격
£ 3,499 ₩ 5,339,000 Unprintable PDF (Single User) - 1 Year License help
1명만 이용할 수 있는 라이센스입니다. DRM(디지털 저작권 관리 시스템) 장착 PDF 파일로, 인증된 PC 1대에서만 열람이 가능하며, 구입일로부터 1년간 유효합니다. PDF 파일은 Copy & Paste 가 되지 않으며, 인쇄 또한 불가능합니다.
£ 3,899 ₩ 5,949,000 PDF (Departmental - 5 Users) - 1 Year License help
동일 사업장(소재지) 내 5명까지 이용할 수 있는 라이센스입니다. DRM(디지털 저작권 관리 시스템) 장착 PDF 파일로, 인증된 PC에서만 열람이 가능하며, 구입일로부터 1년간 유효합니다. PDF파일은 Copy & Paste가 되지 않으며, 인쇄는 1명당 1회에 한해 가능합니다. 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
£ 4,999 ₩ 7,627,000 PDF (Site License) help
동일 사업장(소재지) 내 모든 분이 이용할 수 있는 라이센스입니다. 이용 인원수 제한은 없습니다. PDF 파일은 Copy & Paste 가 되지 않습니다. DRM(디지털 저작권 관리시스템)은 적용되어 있지 않지만, PDF 인쇄는 1명당 1회에 한해 가능합니다. 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
£ 6,999 ₩ 10,679,000 PDF (Global Site License - Includes Free Datasets) help
동일 기업의 전세계 분들이 이용할 수 있는 라이센스입니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste 가 되지 않습니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



의약품 리더 시리즈 : 의약품 위탁생산기관(CMO) 시장의 상위 50사(2018년) : 재무 실적, 서비스, 생산능력, 기업인수합병(M&A), SWOT 분석 Pharma Leader Series: Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market 2018: Financial Performances, Services, Capacities, Mergers & Acquisitions, SWOT Analysis
발행일 : 2018년 09월 페이지 정보 : 영문 257 Pages

세계 주요 의약품 위탁생산기관(CMO : Contract Manufacturing Organisations) 50사의 개요를 제공하며, 시장 전체의 기본 구조 및 촉진·억제요인 조사, 각 기업의 위탁생산 서비스 개요 및 생산능력, 최근 재무 실적, 최근 주요 자본거래·사업 확대 동향, SWOT 분석 및 매출 예측 등의 정보를 정리하여 전해드립니다.

제1장 조사 개요

제2장 서론 : 의약품 위탁생산 시장

  • 위탁생산기업이 제공하는 서비스란?
  • 의약품 위탁생산 시장
  • 의약품 위탁생산 시장의 촉진·억제요인

제3장 세계의 주요 의약품 위탁생산기관(CMO)

  • Alcami Corporation : 의약품 개발·위탁생산기관(CDMO : Contract Development and Manufacturing Organization)
  • AbbVie Contract Manufacturing
  • Aenova Group
  • Aesica Pharmaceuticals
  • Ajinomoto Althea, Inc.
  • Albany Molecular Research, Inc.
  • Alkermes
  • Almac Group
  • Amatsigroup
  • Aurobindo Pharma
  • Avid Bioservices, Inc.
  • Bayer Healthcare AG
  • Baxter BioPharma Solutions
  • Biomay AG
  • Boehringer Ingelheim Contract Manufacturing
  • Catalent Pharma Solutions - 세계 최대급의 CMO
  • Charles River Laboratories International, Inc.
  • Cardinal Health, Inc.
  • CordenPharma International
  • Daito Pharmaceutical Co., Ltd.
  • Delpharm
  • Divis Laboratories
  • Dr. Reddy's Laboratories Ltd.
  • DPT Laboratories, Ltd.
  • Esteve Qu`mica
  • Evonik Degussa
  • FAMAR Health Care Services
  • Fareva Group
  • FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
  • GlaxoSmithKline plc
  • Pfizer CentreOne
  • Huapont Pharmaceutical Co., Ltd.
  • Lonza
  • Nipro Corporation: 일본의 주요 CMO
  • Paragon Bioservices, Inc.
  • Patheon - 세계 3대 CMO의 하나
  • Recipharm
  • F. Hoffman-La Roche Ltd.
  • Royal DSM
  • Shandong Xinhua Pharmaceutical
  • Siegfried
  • TEVA Pharmaceutical, Ltd.
  • Therapure Biopharma, Inc.
  • UPM Pharmaceuticals
  • Vetter Pharmaceutical
  • Xcelience, LLC
  • Xcellerex, Inc.
  • Piramal Pharma Solutions
  • Zhejiang Hisun Pharmaceutical
  • Zhejiang Huahai Pharmaceuticals

제4장 결론

  • 최근 CMO 시장의 성장을 촉진하고 있는 요인은 무엇인가?
  • 성장 전략 : 주요 CMO의 전망
  • 바이오의약품 제조 서비스의 높은 수요
  • 신규 기술에 대한 투자
  • 원료의약품(API) 제조업체의 전망

부록

KSA 18.11.13

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Table

  • Table 2.1: Benefits and Drawbacks to Outsourcing Pharmaceutical Manufacturing, 2017
  • Table 2.2: Contract Manufacturing Market Total Revenue: Total Revenue ($bn), Annual Growth (%), 2014-2016
  • Table 2.3: Contract Manufacturing Market by Service: Market Size ($bn), Market Share (%), 2016
  • Table 2.4: Contract Manufacturing Market by Leading Country: Market Size ($bn), Market Share (%), 2016
  • Table 2.5: Contract Manufacturing Market Forecast by Service: Market Size ($bn), Market Share (%), CAGR (%), 2016, 2021 and 2027
  • Table 2.6: Leading Pharmaceutical Contract Manufacturing Organisations: Rank, Revenue ($m), Market Share (%), 2016
  • Table 3.1: Catalent Details, 2016
  • Table 3.2: Catalent Facility Details, 2016
  • Table 3.3: Catalent Financial Performance: Revenue ($m), Annual Growth Rates (%), CAGR (%), 2011-2016
  • Table 3.4: Catalent Financial Performance by Product Type: Revenue ($m), Revenue Share (%), 2016
  • Table 3.5: Catalent Financial Performance by Division: Revenue ($m), Annual Growth Rate (%), Revenue Share (%), CAGR (%), 2011-2016
  • Table 3.6: Catalent New Products Launch: New Products, Annual growth (%), CAGR (%), 2012-2016
  • Table 3.7: Catalent Pharma SWOT Analysis, 2017
  • Table 3.8: Forecast Catalent Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2021
  • Table 3.9: Forecast Catalent Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2021-2027
  • Table 3.10: Forecast Catalent Pharmaceutical Manufacturing by Division: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2021
  • Table 3.11: Forecast Catalent Pharmaceutical Manufacturing by Division: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2022-2027
  • Table 3.12: Patheon Details, 2016
  • Table 3.13: Patheon Manufacturing Facilities, 2017
  • Table 3.14: Patheon Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rates (%), CAGRs (%), 2011-2016
  • Table 3.15: Patheon: SWOT Analysis, 2016
  • Table 3.16: Forecast Patheon Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2016-2027
  • Table 3.17: Baxter BioPharma Solutions Details, 2016
  • Table 3.18: Baxter BioPharma Solutions: Facilities and Services Offered, 2016
  • Table 3.19: Baxter BioPharma Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2011-2016
  • Table 3.20: Baxter BioPharma Solutions SWOT Analysis, 2016
  • Table 3.21: Forecast Baxter BioPharma Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2027
  • Table 3.22: AbbVie Contract Manufacturing: Details, 2016
  • Table 3.23: AbbVie Contract Manufacturing Facility Capabilities, 2016
  • Table 3.24: AbbVie Pharmaceutical Manufacturing: Revenue ($m) Annual Growth Rate (%), 2011-2016
  • Table 3.25: AbbVie Contract Manufacturing SWOT Analysis, 2016
  • Table 3.26: Forecast AbbVie Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2027
  • Table 3.27: Pfizer CentreOne Details, 2016
  • Table 3.28: Pfizer CentreSource: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2011-2016
  • Table 3.29: Pfizer CentreOne SWOT Analysis, 2016
  • Table 3.30: Forecast Pfizer CentreOne Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2027
  • Table 4.1: Lonza Details, 2016
  • Table 4.2: Selected Lonza Pharmaceutical and Biotech Manufacturing and Development Agreements, 2010-2015
  • Table 4.3: Lonza Pharma & Biotech Department: Revenue ($m), Operating Profit ($m), CAGR (%), Operating Margin (%), 2011-2016
  • Table 4.4: ADCs Approved and in Late Stage Clinical Development, 2014
  • Table 4.5: Lonza SWOT Analysis, 2016
  • Table 4.6: Forecast Lonza Pharma & Biotech: Revenue ($m), Operating Profit ($m), CAGR (%), Operating Margin (%), 2016-2021
  • Table 4.7: Forecast Lonza Pharma & Biotech: Revenue ($m), Operating Profit ($m), CAGR (%), Operating Margin (%), 2022-2027
  • Table 4.8: Evonik Degussa Details, 2016
  • Table 4.9: Evonik Health and Nutrition: R&D and Production Sites by Region, 2016
  • Table 4.10: Evonik Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2011-2016
  • Table 4.11: Evonik Pharmaceutical Manufacturing: SWOT Analysis, 2016
  • Table 4.12: Forecast Evonik Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2016-2027
  • Table 4.13: Royal DSM Details, 2016
  • Table 4.14: Royal DSM Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%) 2011-2016
  • Table 4.15: DSM Pharmaceutical Products (DPP)/DPx Holdings Division: Revenue ($m), Annual Growth (%), CAGR (%), 2011-2016
  • Table 4.16: DSM Sinochem Pharmaceuticals (DSP): Revenue ($m), Annual Growth (%), CAGR (%), 2011-2016
  • Table 4.17: DSM Pharmaceutical Manufacturing: SWOT Analysis, 2016
  • Table 4.18: Forecast Royal DSM Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 4.19: Forecast Royal DSM Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2022-2027
  • Table 4.20: Boehringer Ingelheim Biopharmaceuticals Details, 2016
  • Table 4.21: Boehringer Ingelheim Total Pharmaceutical Manufacturing Capacity: Reactor Size and Number of Units by CMO Service, 2014
  • Table 4.22: Products Developed by Boehringer Ingelheim Biopharmaceuticals, 1983-2014
  • Table 4.23: Boehringer Ingelheim Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2011-2016
  • Table 4.24: Boehringer Ingelheim: SWOT Analysis, 2016
  • Table 4.25: Forecast Boehringer Ingelheim Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2016-2027
  • Table 4.26: Fareva Details, 2016
  • Table 4.27: Fareva Manufacturing Facilities, 2016
  • Table 4.28: Fareva Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2011-2016
  • Table 4.29: Fareva: SWOT Analysis, 2016
  • Table 4.30: Forecast Fareva Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2016-2027
  • Table 4.31: Aenova Group Details, 2016
  • Table 4.32: Aenova Group Manufacturing Capacity by Dosage Form, 2016
  • Table 4.33: Aenova Group Manufacturing Facility Details, 2016
  • Table 4.34: Aenova Group Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rates (%), CAGR (%), 2011-2016
  • Table 4.35: Aenova Group SWOT Analysis, 2016
  • Table 4.36: Forecast Aenova Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rates (%), CAGRs (%), 2016-2021
  • Table 4.37: Forecast Aenova Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rates (%), CAGRs (%), 2022-2027
  • Table 4.38: Famar Details, 2016
  • Table 4.39: Famar Pharmaceutical Manufacturing Facilities, 2016
  • Table 4.40: Famar Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2011-2016
  • Table 4.41: Famar: SWOT Analysis, 2016
  • Table 4.42: Forecast Famar Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2016-2027
  • Table 4.43: Vetter Details, 2016
  • Table 4.44: Vetter Pharmaceutical Facilities, 2016
  • Table 4.45: Vetter Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2011-2016
  • Table 4.46: Vetter: SWOT Analysis, 2016
  • Table 4.47: Forecast Vetter Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2016-2027
  • Table 4.48: Almac Details, 2016
  • Table 4.49: Almac Pharmaceutical Manufacturing Facilities Details, 2016
  • Table 4.50: Almac Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rates (%), CAGRs (%), 2011-2016
  • Table 4.51: Almac: SWOT Analysis, 2016
  • Table 4.52: Forecast Almac Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rates (%), CAGR (%), 2016-2021
  • Table 4.53: Forecast Almac Pharmaceuticals: Revenue ($m), Operating Profit ($m), Annual Growth Rates (%), CAGRs (%), 2022-2027
  • Table 4.54: Delpharm Details, 2016
  • Table 4.55: Delpharm: Facilities and Services, 2016
  • Table 4.56: Delpharm: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2011-2016
  • Table 4.57: Delpharm: SWOT Analysis, 2016
  • Table 4.58: Forecast Delpharm Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2016-2027
  • Table 4.59: Siegfried Details, 2016
  • Table 4.60: Siegfried Pharmaceutical Manufacturing Facilities Details, 2016
  • Table 4.61: Siegfried Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2011-2016
  • Table 4.62: Siegfried Pharmaceutical Manufacturing Revenue by Service: API Revenue ($m), Drug Product Revenue ($m), Annual Growth Rates (%), CAGRs (%), 2011-2016
  • Table 4.63: Siegfried: SWOT Analysis, 2016
  • Table 4.64: Forecast Siegfried Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Annual Growth Rates (%), CAGRs (%), Operating Margin (%), 2016-2021
  • Table 4.65: Forecast Siegfried Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Annual Growth Rates (%), CAGRs (%), Operating Margin (%), 2022-2027
  • Table 4.66: CordenPharma Details, 2016
  • Table 4.67: CordenPharma Facilities and Service Details, 2016
  • Table 4.68: Corden Pharmaceuticals: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2011-2016
  • Table 4.69: Corden Pharmaceuticals SWOT Analysis, 2016
  • Table 4.70: Recipharm Details, 2016
  • Table 4.71: Recipharm: Facility Details and Services, 2016
  • Table 4.72: Recipharm: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2011-2016
  • Table 4.73: Recipharm Manufacturing Revenue by Client Size: Revenue ($m), Share of Total Revenues (%), 2016
  • Table 4.74: Recipharm Manufacturing Revenue Distribution: Customer Revenue ($m), Share of Total Revenues (%), 2016
  • Table 4.75: Recipharm: SWOT Analysis, 2016
  • Table 4.76: Recipharm: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2016-2021
  • Table 4.77: Recipharm: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2022-2027
  • Table 4.78: Aesica Details, 2016
  • Table 4.79: Aesica Pharmaceuticals: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2011-2016
  • Table 4.80: Aesica SWOT Analysis, 2016
  • Table 4.81: Aesica Pharmaceuticals: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2016-2021
  • Table 4.82: Aesica Pharmaceuticals: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2022-2027
  • Table 5.1: Nipro Pharma Details, 2016
  • Table 5.2: Nipro Pharmaceutical Contract Manufacturing Capabilities: 2011-2016
  • Table 5.3: Nipro Pharmaceutical Contract Manufacturing: Annual Production Capacity, 2016
  • Table 5.4: Nipro Pharmaceutical Contract Manufacturing Financial Performance: Revenue ($m), Revenue (¥m), Operating Profit ($m), Operating Profit (¥m), Operating Margin (%), Annual Growth Rates (%), CAGR (%), 2011-2016
  • Table 5.5: Nipro Pharmaceutical Contract Manufacturing SWOT Analysis, 2016
  • Table 5.6: Forecast Nipro Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rate (%), CAGR (%), 2016-2021
  • Table 5.7: Forecast Nipro Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rate (%), CAGR (%), 2022-2027
  • Table 5.8: Daito Pharmaceuticals: Details, 2016
  • Table 5.9: Daito Pharmaceuticals Financial Performance: Revenue ($m), Revenue (¥m), Operating Profit ($m), Operating Profit (¥m), Operating Margin (%), Annual Growth Rates (%), CAGR (%), 2011-2016
  • Table 5.10: Daito Pharmaceuticals SWOT Analysis, 2016
  • Table 5.11: Forecast Daito Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rate (%), CAGR (%), 2016-2021
  • Table 5.12: Forecast Daito Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rate (%), CAGR (%), 2022-2027
  • Table 6.1: Teva API Details, 2016
  • Table 6.2: Teva API: Site Acquisitions, 1980- 2011
  • Table 6.3: Teva API: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2011-2016
  • Table 6.4: Teva API SWOT Analysis, 2016
  • Table 6.5: Forecast Teva API Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2027
  • Table 6.6: Esteve Química Details, 2016
  • Table 6.7: Esteve Química SWOT Analysis, 2016
  • Table 6.8: Euticals Details, 2016
  • Table 6.9: Euticals Facility Details: Production Capacity (m3) and Key Products, 2016
  • Table 6.10: Euticals Cumulative Regulatory Filings by Region/Country: Filings, Share of Total (%), 2016
  • Table 6.11: Euticals: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2011-2016
  • Table 6.12: Euticals Revenue by Product Class: Revenue ($m), Share of Total (%), 2016
  • Table 6.13: Euticals Revenue by Region: Revenue ($m), Share of Total (%), 2016
  • Table 6.14: Euticals SWOT Analysis, 2016
  • Table 6.15: Forecast Euticals Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2027
  • Table 7.1: Zhejiang Hisun Pharmaceuticals Details, 2016
  • Table 7.2: Zhejiang Hisun Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2011-2016
  • Table 7.3: Zhejiang Hisun Manufacturing: SWOT Analysis, 2016
  • Table 7.4: Forecast Zhejiang Hisun Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2027
  • Table 7.5: Zhejiang Huahai Pharmaceuticals Details, 2016
  • Table 7.6: Zhejiang Huahai Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2011-2016
  • Table 7.7: Zhejiang Huahai Contract Manufacturing: SWOT Analysis, 2016
  • Table 7.8: Forecast Zhejiang Huahai Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2027
  • Table 7.9: Shandong Xinhua Pharmaceuticals Details, 2016
  • Table 7.10: Shandong Xinhua Pharmaceutical Production Capacity by Dosage Form, 2016
  • Table 7.11: Shandong Xinhua: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2011-2016
  • Table 7.12: Shandong Xinhua Revenue Share by Geographic Region: Revenue Share (%), 2016
  • Table 7.13: Shandong Xinhua Manufacturing: SWOT Analysis, 2016
  • Table 7.14: Forecast Shandong Xinhua Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2027
  • Table 8.1: Aurobindo Pharma Details, 2016
  • Table 8.2: Aurobindo Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2011-2016
  • Table 8.3: Aurobindo Contract Manufacturing Revenue by API Class: Revenue ($m), Revenue Share (%), 2014
  • Table 8.4: Aurobindo Contract Manufacturing: SWOT Analysis, 2016
  • Table 8.5: Forecast Aurobindo Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2027
  • Table 8.6: Divis Laboratories Details, 2016
  • Table 8.7: Divis Laboratories: Facility Details, Production Capacity and Services, 2016
  • Table 8.8: Divis Laboratories: Revenue ($m), EBITDA ($m), EBITDA Margin (%), Annual Growth Rate (%), CAGR (%), 2011-2016
  • Table 8.9: Divis Laboratories Revenue Distribution: Revenue ($m), Share of Total (%), 2016
  • Table 8.10: Divis Laboratories Revenue by Region: Revenue ($m), Share of Total (%), 2016
  • Table 8.11: Divis Laboratories Contract Manufacturing: SWOT Analysis, 2016
  • Table 8.12: Forecast Divis Laboratories Contract Manufacturing: Revenue ($m), EBITDA ($m), EBITDA Margin (%), Annual Growth Rate (%), CAGR (%), 2016-2021
  • Table 8.13: Forecast Divis Laboratories Contract Manufacturing: Revenue ($m), EBITDA ($m), EBITDA Margin (%), Annual Growth Rate (%), CAGR (%), 2022-2027
  • Table 8.14: Dr. Reddy's Laboratories Details, 2016
  • Table 8.15: Dr. Reddy's Laboratories Cumulative Drug Master File (DMF) Applications: Applications Accepted by Region, Regional Share (%), 1987-2014
  • Table 8.16: Dr. Reddy's Laboratories Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2011-2016
  • Table 8.17: Dr. Reddy's Laboratories Drug Master File (DMF) Applications: Applications Accepted by Region, Regional Share (%), FY 2016
  • Table 8.18: Dr. Reddy's Laboratories: Contract Manufacturing Revenue ($m) by Regional Market and Revenue Share (%), FY 2016
  • Table 8.19: Dr. Reddy's Laboratories: SWOT Analysis, 2016
  • Table 8.20: Forecast Dr. Reddy's Laboratories Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2027
  • Table 9.1: Top Five Developed and Emerging Market CMOs: Grouped Revenue ($m), Annual Growth Rate (%), CAGR (%), 2011-2016
  • Table 9.2: CMOs by Absolute Change in Revenue ($m): Annual Revenue ($m), Absolute Change in Revenue ($m), 2011-2016
  • Table 9.3: Leading CMOs: Combined Annual Revenue ($m), Annual Growth (%), Market Share (%), CAGR (%), 2016-2027
  • Table 9.5: CMOs by Absolute Change in Revenue: Annual Revenue ($m), Absolute Change in Revenue ($m), 2015-2020
  • Table 9.6: CMOs by Absolute Change in Revenue: Annual Revenue ($m), Absolute Change in Revenue ($m), 2021-2027

List of Figures

  • Figure 1.1: Segmentation of Contract Manufacturing Organisations, 2017
  • Figure 2.1: Selected Services Contracted to CMOs by Developmental Stage, 2017
  • Figure 2.2: Contract Manufacturing Market Total Revenue: Total Revenue ($bn), 2014-2016
  • Figure 2.3: Contract Manufacturing Market by Service: Market Share (%), 2016
  • Figure 2.4: Contract Manufacturing Market by Leading Country: Market Share (%), 2016
  • Figure 2.5: Contract Manufacturing Market Forecast by Service: Market Size ($bn), 2016, 2021 and 2027
  • Figure 2.6: Pharmaceutical Contract Manufacturing: Drivers and Restraints, 2017-2027
  • Figure 3.1: Catalent Facilities by Region, 2016
  • Figure 3.2: Catalent Facilities by Service Offered, 2016
  • Figure 3.3: Catalent Financial Performance: Revenue ($m), 2011-2016
  • Figure 3.4: Catalent Financial Performance by Product Type: Revenue Share (%), 2016
  • Figure 3.5: Catalent Financial Performance by Division: Revenue ($m), 2011-2016
  • Figure 3.6: Catalent New Products Launch: New products, 2012-2016
  • Figure 3.7: Forecast Catalent Pharmaceutical Manufacturing: Revenue ($m), 2016-2021
  • Figure 3.8: Forecast Catalent Pharmaceutical Manufacturing: Revenue ($m), 2022-2027
  • Figure 3.9: Forecast Catalent Pharmaceutical Manufacturing by Division: Revenue ($m), 2016-2027
  • Figure 3.10: Patheon Pharmaceutical Development Projects (%) by Phase, 2016
  • Figure 3.11: Patheon Pharmaceutical Manufacturing Projects by Client Size: Proportion of Total Revenue (%), 2016
  • Figure 3.12: Patheon Pharmaceutical Manufacturing: Revenue ($m), 2011-2016
  • Figure 3.13: Forecast Patheon Pharmaceutical Manufacturing: Revenue ($m), 2016-2027
  • Figure 3.14: Forecast DPx Holdings Performance by Equity Partner: Revenue ($m), 2016-2027
  • Figure 3.15: Baxter BioPharma Manufacturing: Revenue ($m), 2011-2016
  • Figure 3.16: Forecast Baxter BioPharma Manufacturing: Revenue ($m), 2016-2027
  • Figure 3.17: AbbVie Pharmaceutical Manufacturing: Revenue ($m)*, 2011-2016
  • Figure 3.18: Forecast AbbVie Pharmaceutical Manufacturing: Revenue ($m), 2016-2027
  • Figure 3.19: Pfizer CentreOne: Revenue ($m), 2011-2016
  • Figure 3.20: Forecast Pfizer CentreOne Manufacturing: Revenue ($m), 2016-2027
  • Figure 4.1: Lonza Pharma & Biotech: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2011-2016
  • Figure 4.2: Lonza Custom Manufacturing by Regional Market: Revenue Share (%), 2016
  • Figure 4.3: Forecast Lonza Pharma & Biotech: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2016-2021
  • Figure 4.4: Forecast Lonza Pharma & Biotech: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2022-2027
  • Figure 4.5: Evonik Health and Nutrition: R&D and Production Sites (%) by Region, 2016
  • Figure 4.6: Evonik Pharmaceutical Manufacturing: Revenue ($m), 2011-2016
  • Figure 4.7: Forecast Evonik Pharmaceutical Manufacturing: Revenue ($m), 2016-2027
  • Figure 4.8: Royal DSM Pharmaceutical Manufacturing: Revenue ($m), 2011-2016
  • Figure 4.9: DSM Pharmaceutical Products (DPP)/ DPx Holdings Division: Revenue ($m), 2011-2016
  • Figure 4.10: DSM Sinochem Pharmaceuticals (DSP): Revenue ($m), 2011-2016
  • Figure 4.11: Forecast DPx Holdings Performance by Equity Partner: Revenue ($m), 2016-2027
  • Figure 4.12: Forecast Royal DSM Pharmaceutical Manufacturing: Revenue ($m), 2016-2027
  • Figure 4.13: Boehringer Ingelheim Pharmaceutical Manufacturing: Revenue ($m), 2011-2016
  • Figure 4.14: Forecast Boehringer Ingelheim Pharmaceutical Manufacturing: Revenue ($m), 2016-2027
  • Figure 4.15: Fareva Pharmaceutical Manufacturing: Revenue ($m), 2011-2016
  • Figure 4.16: Forecast Fareva Pharmaceutical Manufacturing: Revenue ($m), 2016-2027
  • Figure 4.17: Aenova Group Pharmaceutical Manufacturing: Revenue ($m), 2011-2016
  • Figure 4.18: Forecast Aenova Pharmaceutical Manufacturing: Revenue ($m), 2016-2021
  • Figure 4.19: Forecast Aenova Pharmaceutical Manufacturing: Revenue ($m), 2022-2027
  • Figure 4.20: Famar Pharmaceutical Manufacturing: Revenue ($m), 2011-2016
  • Figure 4.21: Forecast Famar Pharmaceutical Manufacturing: Revenue ($m), 2016-2027
  • Figure 4.22: Vetter Pharmaceutical Manufacturing: Revenue ($m), 2011-2016
  • Figure 4.23: Forecast Vetter Pharmaceutical Manufacturing: Revenue ($m), 2016-2027
  • Figure 4.24: Almac Pharmaceutical Manufacturing: Revenue ($m), 2011-2016
  • Figure 4.25: Forecast Almac Pharmaceutical Manufacturing: Revenue ($m), 2016-2021
  • Figure 4.26: Forecast Almac Pharmaceuticals: Revenue ($m), 2022-2027
  • Figure 4.27: Delpharm: Revenue ($m), 2011-2016
  • Figure 4.28: Forecast Delpharm Pharmaceutical Manufacturing: Revenue ($m), 2016-2027
  • Figure 4.29: Siegfried Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2011-2016
  • Figure 4.30: Siegfried Pharmaceutical Manufacturing Revenue by Service: API Revenue ($m), Drug Product Revenue ($m), 2011-2016
  • Figure 4.31: Siegfried Pharmaceutical Manufacturing Revenue by Customer Location: Revenue Share (%), 2015
  • Figure 4.32: Siegfried Pharmaceutical Manufacturing Revenue by Customer Location: Revenue Share (%), 2016
  • Figure 4.33: Forecast Siegfried Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2016-2021
  • Figure 4.34: Forecast Siegfried Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2022-2027
  • Figure 4.35: Corden Pharmaceuticals: Revenue ($m), 2011-2016
  • Figure 4.36: Recipharm: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2011-2016
  • Figure 4.37: Recipharm Manufacturing Revenue by Client: Share of Total Revenues (%), 2016
  • Figure 4.38: Recipharm Manufacturing Revenue Distribution: Customer Revenue ($m), 2016
  • Figure 4.39: Recipharm: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2016-2021
  • Figure 4.40: Recipharm: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2022-2027
  • Figure 4.41: Aesica Pharmaceuticals: Revenue ($m)*, Operating Profit ($m)*, Operating Margin (%), 2011-2016
  • Figure 4.42: Aesica Pharmaceuticals: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2016-2021
  • Figure 4.43: Aesica Pharmaceuticals: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2022-2027
  • Figure 5.1: Nipro Pharmaceutical Contract Manufacturing Capabilities: Orally Administered Drugs, Injectables, External Preparations, 2011-2016
  • Figure 5.2: Nipro Pharmaceuticals Financial Performance: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2011-2016
  • Figure 5.3: Forecast Nipro Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2016-2021
  • Figure 5.4: Forecast Nipro Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2022-2027
  • Figure 5.5: Daito Pharmaceuticals Financial Performance: Revenue (¥m), Operating Profit (¥m), Operating Margin (%), 2011-2016
  • Figure 5.6: Forecast Daito Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2016-2021
  • Figure 5.7: Forecast Daito Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2022-2027
  • Figure 6.1: Teva API: Revenue ($m), 2011-2016
  • Figure 6.2: Forecast Teva API Manufacturing: Revenue ($m), 2016-2027
  • Figure 6.3: Euticals Cumulative Regulatory Filings by Region/Country: Share of Total (%), 2016
  • Figure 6.4: Euticals: Revenue ($m), 2011-2016
  • Figure 6.5: Euticals Revenue by Product Class: Share of Total Revenues (%), 2016
  • Figure 6.6: Euticals Revenue by Region: Share of Total Revenues (%), 2016
  • Figure 6.7: Forecast Euticals Pharmaceutical Manufacturing: Revenue ($m), 2016-2027
  • Figure 7.1: Zhejiang Hisun Contract Manufacturing: Revenue ($m), 2011-2016
  • Figure 7.2: Forecast Zhejiang Hisun Contract Manufacturing: Revenue ($m), 2016-2027
  • Figure 7.3: Zhejiang Huahai Contract Manufacturing: Revenue ($m), 2011-2016
  • Figure 7.4: Zhejiang Huahai Contract Manufacturing: Revenue ($m), 2016-2027
  • Figure 7.5: Shandong Xinhua: Revenue ($m), 2011-2016
  • Figure 7.6: Shandong Xinhua Revenue Share by Geographic Region: Revenue Share (%), 1H 2016
  • Figure 7.7: Forecast Shandong Xinhua Manufacturing: Revenue ($m), 2016-2027
  • Figure 8.1: Aurobindo Contract Manufacturing: Revenue ($m), 2011-2016
  • Figure 8.2: Aurobindo Contract Manufacturing: Revenue Share (%), 2014
  • Figure 8.3: Forecast Aurobindo Contract Manufacturing: Revenue ($m), 2016-2027
  • Figure 8.4: Divis Laboratories Contract Manufacturing: Revenue ($m), EBTDA ($m), EBITDA Margin (%), 2011-2016
  • Figure 8.5: Divis Laboratories Revenue Distribution: Revenue ($m), 2016
  • Figure 8.6: Divis Laboratories Revenue by Region: Share of Total (%), 2016
  • Figure 8.7: Forecast Divis Laboratories Contract Manufacturing: Revenue ($m), EBITDA ($m), EBITDA Margin (%), 2016-2021
  • Figure 8.8: Forecast Divis Laboratories Contract Manufacturing: Revenue ($m), EBITDA ($m), EBITDA Margin (%), 2022-2027
  • Figure 8.9: Dr. Reddy's Laboratories Cumulative Drug Master File (DMF) Applications: Accepted by Region (%), 1987-2016
  • Figure 8.10: Dr. Reddy's Laboratories Contract Manufacturing: Revenue ($m), 2011-2016
  • Figure 8.11: Dr. Reddy's Laboratories Drug Master File (DMF) Applications: Accepted Applications by Region (%), FY 2015
  • Figure 8.12: Dr. Reddy's Laboratories Contract Manufacturing Revenue: Regional Revenue Share (%), FY 2016
  • Figure 8.13: Forecast Dr. Reddy's Laboratories Contract Manufacturing: Revenue ($m), 2016-2027
  • Figure 9.1: Top Five Developed and Emerging Market CMOs: Grouped Revenue ($m), 2011-2016
  • Figure 9.2: Top Ten Global CMOs by Absolute Change in Revenue: Absolute Change in Revenue ($m), 2011-2016
  • Figure 9.3: Leading CMOs: Combined Annual Revenue ($bn), 2016-2027
  • Table 9.4: Top Five Developed and Emerging Market CMOs: Grouped Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2027
  • Figure 9.4: Top Five Developed and Emerging Market CMOs: Grouped Revenue ($m), 2016-2027
  • Figure 9.5: Top Ten Global CMOs by Absolute Change in Revenue: Absolute Change in Revenue ($m), 2015-2020
  • Figure 9.6: Top Ten Global CMOs by Absolute Change in Revenue: Absolute Change in Revenue ($m), 2021-2027

Companies Listed

  • Abbott Laboratories
  • Abic
  • AbbVie
  • Actavis
  • Adamas Pharmaceuticals
  • Aegerion
  • Aenova Group
  • Aesica Pharmaceuticals
  • Agennix
  • Aguettant
  • AlgoNomics
  • Alliance Medical Products
  • Almac Group
  • Alpharma
  • Amgen
  • AMYRA Biotech
  • Andeno
  • Apexigen
  • Aptuit
  • Archimica
  • Arecor
  • ArGEN-X
  • Astellas
  • AstraZeneca
  • Athera Biotechnologies
  • Aurobindo Pharma
  • Avalanche Biotechnologies
  • Banner Life Sciences
  • BaroFold
  • Barr-Pliva
  • BASF
  • Baxter BioPharma Solutions
  • Bayer
  • BC Partners
  • Becton and Dickinson (BD)
  • Beijing Double-Crane Pharmaceutical
  • Bentley
  • Biocraft
  • Biogal
  • Bionomics
  • Biotest
  • BioWa
  • Boehringer Ingelheim
  • Bridgepoint Capital
  • Bristol-Myers Squibb (BMS)
  • Britest
  • Canyon
  • Carbogen Amcis
  • Cardinal Health
  • Catalent
  • Celladon
  • Celldex Therapeutics
  • Celsion
  • CEVEC Pharmaceuticals
  • Chemtrix BV
  • China National Pharmaceutical Group (SInopharm)
  • Chirotech
  • Circadian Technologies
  • Cleveland BioLabs
  • Cobra Biomanufacturing
  • Companies House
  • CordenPharma
  • Corvette Pharmaceutical Services
  • Daiichi Sankyo
  • Daito
  • DecImmune Therapeutics
  • Delmas Perfusion
  • Delpharm
  • Divis Laboratories
  • DPx Holdings
  • Dr. Reddy's Laboratories
  • Dragenopharm Apotheker Püschl and Swiss Caps
  • Eclipse Therapeutics
  • Eisai
  • Eli Lilly
  • EmulTech
  • Esteve Química
  • Euro Vital Pharma
  • Euticals
  • Evonik Degussa
  • Excella
  • Exelixis
  • Famar
  • Fareva
  • Farmaprojects
  • Frazier Healthcare
  • Fuyang Xinghai Investment
  • Genentech
  • Genzyme
  • GSK
  • Corixa
  • Haupt Pharma
  • Health Canada
  • Hejiang Jiang Yuan Tang Biotechnology
  • Human Genome Sciences
  • ICI
  • Immune Pharmaceuticals
  • Immunomedics
  • Index Ventures
  • Indoco Remedies
  • Intellect Neurosciences
  • International Chemical Investors Group
  • Ivax API
  • JK Pharmaceutical
  • JLL Partners
  • Johnson & Johnson (J&J)
  • Kadmon
  • Laboratoires Besins
  • Lanxess Corporation
  • LBO Italia Investimenti s.r.l
  • Lonza
  • Marinopoulos Group.
  • MedImmune
  • Merck KGaA
  • Merck Serono
  • Mesoblast
  • Molecular Partners
  • Moody's Corporation
  • Mylan
  • Nipro Corporation
  • Novartis
  • Novasep
  • Novozymes
  • NPS
  • OctoPlus
  • OncoMed Pharmaceuticals
  • Opthea
  • Osiris Therapeutics
  • Otsuka Pharmaceutical
  • Pantec
  • Patheon
  • Perrigo
  • PFC
  • Pfizer
  • Pharmacia
  • Pharmacyclis
  • Pharmintraco
  • Piramal
  • Plantex
  • Poli Industria Chimica
  • Progenics Pharmaceuticals
  • Prosintex
  • R5 Pharmaceuticals
  • RAG AG
  • Ranbaxy Labs
  • Recipharm
  • Regeneus
  • Relthy Laboratórios
  • Relypsa
  • Respirics
  • Rexim
  • Roche
  • Royal DSM
  • Sandoz
  • Sanofi
  • Sanwa Kagaku Kenkyusho
  • Schering
  • ScinoPharm
  • Seattle Genetics
  • Sentry BioPharma Services
  • Servier
  • Shandong Tianda Biological Pharmaceutica
  • Shandong Xinhua Pharmaceutical
  • Shanghai Pharmaceutical
  • ShangPharma
  • Shire
  • Sicor
  • Siegfried
  • Sigmar Italia
  • Silverfleet Capital
  • Sinochem
  • SkyePharma
  • Solvay
  • Sun Pharma
  • Supernus Pharmaceuticals
  • SurModics
  • Swedbank
  • Swedish Orphan Biovitrium AB (Sobi)
  • Synkem
  • Syntex
  • Synthon
  • Takeda
  • Temmler Group
  • Tessenderlo Group
  • Teva Pharmaceutical Industries
  • Theramax
  • Tianjin Tianyo Pharmaceuticals
  • Tianma Tianji
  • Tunitas Therapeutics
  • UCB
  • UMN Pharma
  • UniQure
  • Vetter Pharma
  • Vidara
  • ViroPharma
  • Vivante GMP Solutions
  • VTU Technology
  • West Pharma
  • Wockhardt
  • XOMA
  • Yiwu Huayi Investment
  • Zhangjiang Biotech & Pharmaceutical Base Company
  • Zhejiang Hisun Pharmaceutical
  • Zhejiang Huahai Pharmaceuticals

Organizations Mentioned in the Report:

  • Agence Nationale de sécurité du Médicament et des produits de santé (ANSM)
  • Agência Nacional de Vigilância Sanitária (ANVISA)
  • Biomedical Advanced Research and Development Authority (BARDA)
  • Eindhoven University of Technology
  • European Medicines Agency (EMA)
  • Générique Même Médicament (GEMME)
  • Japanese Ministry of Health Labor and Welfare (MHWL)
  • Japanese Pharmaceutical and Medical Devices Agency (PMDA)
  • NIH CRM
  • Sanquin Blood Supply Foundation
  • UK Health and Safety Executive
  • UK Medicines and Healthcare Products Regulatory Agency (MHRA)
  • University College London (UCL)
  • University of Bradford
  • University of Durham
  • University of Leeds
  • US Food and Drug Administration (FDsA)

Contract manufacturing represents the largest sector of the pharma outsourcing industry. Pharmaceutical companies have sought to take advantage of the benefits of contract manufacturing - lower costs, increased flexibility and external expertise - to focus resources on core competencies in drug development and marketing.

CMOs are increasingly seen as a strategic partner for pharmaceutical companies, providing a one-stop-shop of services for formulation development and manufacturing throughout the lifecycle of a drug.

The market-leading CMOs have grown through acquisitions and site expansions to offer almost all required services on a global scale. However, there is still a role to be played by specialist CMOs, particularly those that offer biological drug manufacturing services.

This updated study discusses market-leading companies worldwide, as well as the strategies they have employed to develop in recent years. Visiongain's research and analysis explore opportunities and challenges for the top 50 pharma contract manufacturing organisations.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 257-page report you will receive 189 charts - all unavailable elsewhere.

The 257-page report provides clear detailed insight into the leading pharmaceutical contract manufacturing organizations. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

  • Global Pharmaceutical Contract Manufacturing Market Size in 2017
  • Pharmaceutical Contract Manufacturing Market Size in 2017 segmented by national market :
  • US
  • EU
  • China
  • Japan
  • India
  • Brazil
  • Russia
  • South Korea
  • Others
  • Discussion and analysis of factors that drive and restrain the pharmaceutical contract manufacturing market
  • Profiles of the 50 leading pharmaceutical contract manufacturing organizations :
  • AbbVie Contract Manufacturing
  • Aenova Group
  • Aesica Pharmaceuticals
  • Ajinomoto Althea, Inc.
  • Albany Molecular Research, Inc.
  • Alcami Corporation
  • Alkermes plc
  • Almac Group
  • Amatsigroup
  • Aurobindo Pharma Ltd.
  • Avid Bioservices Inc.
  • Bayer AG
  • Baxter Biopharma Solutions
  • Biomay AG
  • Boehringer Ingelheim GmbH
  • Catalent Pharma Solutions Inc.
  • Charles River Laboratories International Inc.
  • Cardinal Health
  • Corden Pharmaceutical
  • Daito Pharmaceutical
  • Delpharm
  • Divis Laboratories Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • DPT Laboratories
  • Esteve Química
  • Evonik Degussa
  • Famar Health Care Services
  • Fareva
  • Fujifilm Diosynth Biotechnologies UK Ltd.
  • GlaxoSmithKline plc
  • Huapont Medical
  • Lonza Group Ltd.
  • Nipro Corporation
  • Paragon Bioservices Inc
  • Patheon Inc
  • Pfizer Inc./Pfizer CentreSource (PCS)
  • Piramal Healthcare L
  • Recipharm A
  • Roche
  • Royal DSM NV
  • Shandong Xinhua Pharmaceutical
  • Siegfried
  • Teva API
  • Therapure Biopharma Inc.
  • UPM Pharmaceuticals Inc.
  • Vetter Pharmacuticals
  • Xcelience LLC
  • Xcellerex LLC
  • Zhejiang Hisun Pharmaceutical
  • Zhejiang Huahai Pharmaceuticals

image1

  • The content of each profile differs, depending on the organization. In general, a profile gives the following information:
  • Overview of the company's contract manufacturing services and operations
  • Analysis of recent financial performance - annual revenue for CMO services, including some data on operating profit and margins
  • Assessment of developments - activities, acquisitions, production capacity, deals, new service offerings and collaborations
  • SWOT analysis - a firm's strengths and weaknesses, as well as opportunities and threats to manufacturing sales growth

Visiongain's study is intended for anyone requiring commercial analyses for pharmaceutical contract manufacturing market. You find data, trends and predictions.

Table of Contents

1. Report Overview

  • 1.1 Leading Contract Manufacturing Organizations (CMOs) Overview
  • 1.2 Benefits of This Report
  • 1.3 How This Report Delivers Information
  • 1.4 Main Questions This Report Answers
  • 1.5 Who is This Report For?
  • 1.6 Methods of Research and Analysis
  • 1.7 Frequently Asked Questions (FAQs)
  • 1.8 Some Associated Reports
  • 1.9 About Visiongain

2. Introduction to Pharmaceutical Contract Manufacturing, 2017

  • 2.1 What Services Do Contract Manufacturers Offer?
    • 2.1.1 Why Do Firms Outsource Manufacturing?
    • 2.1.2 What Is Driving Demand for Contract Manufacturing Services?
  • 2.2 The Pharmaceutical Contract Manufacturing Market, 2017
    • 2.2.1 Where is Supply and Demand Highest for Contract Manufacturing Services?
  • 2.3 Driving and Restrictive Forces for Pharmaceutical Contract Manufacturing
    • 2.3.1 Pharmaceutical Contract Manufacturing: Market Drivers
    • 2.3.2 Pharmaceutical Contract Manufacturing: Market Restraints

3. Leading Contract Manufacturing Organizations

  • 3.1 Alcami Corporation - A Contract Development and Manufacturing Organization
    • 3.1.1 Alcami: Manufacturing Services and Capabilities
    • 3.1.2 Divisional Segmentation - Breakdown of Alcami's Service
    • 3.1.3 Alcami Focuses on Advancing its Analytical Testing Turnaround Time
    • 3.1.4 Alcami Extended its Laboratory Service Program
    • 3.1.5 Alcami: Madison Dearborn Partners
    • 3.1.6 Alcami Expands its Sales Office
    • 3.1.7 Alcami Partnered with Solasia Pharma for Manufacturing Active Pharmaceutical Ingredient
  • 3.2 AbbVie Contract Manufacturing
    • 3.2.1 AbbVie Offers Full-Service Contract Manufacturing
    • 3.2.2 Expanding and Adding New Services: 2017-2018
    • 3.2.3 Biologics and HPAPIs Opportunities for Growth 2017-2028
  • 3.3 Aenova Group
    • 3.3.1 Acquisition of Haupt Creates European CMO Giant
    • 3.3.2 Aenova's Ever Expanding Manufacturing Capacity
    • 3.3.3 Aenova's Competitive Position in the Contract Manufacturing Market: SWOT Analysis 2017
    • 3.3.4 Aenova: New Manufacturing Facilities to Expand Geographic Presence
  • 3.4 Aesica Pharmaceuticals
    • 3.4.1 Aesica Manufactures APIs and Finished Dosage Forms
    • 3.4.2 Acquisitions Drive Revenue Growth, 2012-2017
    • 3.4.3 Partnering with Academia for Innovative Solutions
    • 3.4.4 Growth through Acquisitions and Internal Expansion
    • 3.4.5 Aesica: Opportunities for Expansion
  • 3.5 Ajinomoto Althea, Inc.
    • 3.5.1 Ajinomoto Althea Expands its Manufacturing Capabilities
    • 3.5.2 Ajinomoto: New U.S. Patent for Manufacturing Crystal Monoclonal Antibodies
    • 3.5.3 Ajinomoto Althea Expanding its Manufacturing Capacity
  • 3.6 Albany Molecular Research, Inc.
    • 3.6.1 Acquiring New Businesses to Expand Capabilities and Services
    • 3.6.2 Expanding Business Operations in New Geographies
    • 3.6.3 Collaborations to Enhance Services
    • 3.6.4 AMRI Acquisition of Euticals S.p.a
  • 3.7 Alkermes
    • 3.7.1 Collaboration as a Growth Strategy to Develop and Commercialize Products
    • 3.7.2 Alkermes: Clinical Development Program
  • 3.8 Almac Group
    • 3.8.1 Almac's Manufacturing Services
    • 3.8.2 Almac Adding Capacity Globally
    • 3.8.3 New Services Added 2012-2016
    • 3.8.4 Almac Group: Contract Manufacturing Market Outlook
  • 3.9 Amatsigroup
    • 3.9.1 Amatsi: Contract Manufacturing Agreement
    • 3.9.2 Mergers and Acquisitions to Enhance Market Presence
    • 3.9.3 Amatsigroup Expands its Operations and Product Portfolio
  • 3.10 Aurobindo Pharma
    • 3.10.1 API Manufacturing Services
    • 3.10.2 Aurobindo Pharma: Steady Revenue Growth 2012-2017
    • 3.10.3 Aurobindo Expanding Outside of Antibacterial
    • 3.10.4 Aurobindo: Opportunities for Expansion
  • 3.11 Avid Bioservices, Inc.
    • 3.11.1 Avid Focuses on Expanding its Manufacturing Capacity
    • 3.11.2 Avid Bioservices Selected by Acumen Pharmaceuticals to Lead Process Development and Clinical Manufacture
    • 3.11.3 Avid Bioservices Expands Process Development Capabilities and Laboratory Infrastructure
  • 3.12 Bayer Healthcare AG
    • 3.12.1 Bayer Focuses on Providing Superior Pharmaceutical Services
    • 3.12.2 Bayer Focuses Quality for all the Products and Services Offered by the Company
  • 3.13 Baxter BioPharma Solutions
    • 3.13.1 BioPharma Solutions Offers a Broad Product Portfolio of Sterile Contract Manufacturing Services and Solutions
    • 3.13.2 BioPharma Focuses on Expanding its Manufacturing Capacities
    • 3.13.3 Baxter BioPharma Solutions and SAFC Collaborate on Complete ADC Offering
    • 3.13.4 Baxter BioPharma Solutions Focuses on Research & Development Investments
    • 3.13.5 Baxter BioPharma is the Global Leader in Sterile Fill and Finish
    • 3.13.6 Baxter BioPharma SWOT Analysis
  • 3.14 Biomay AG
    • 3.14.1 Biomay Offers Fully Integrated GMP Capacities
    • 3.14.2 Biomay Focuses on Increasing its Capital
  • 3.15 Boehringer Ingelheim Contract Manufacturing
    • 3.15.1 Expanding Biopharmaceuticals Manufacturing Services in China
    • 3.15.2 Production Through to Fill and Finished Biopharmaceuticals
    • 3.15.3 A Track Record of Production for 29 Biopharma Products
    • 3.15.4 Increasing Revenue from Contract Manufacturing, 2012-2017
    • 3.15.5 Pulling Out of Small Molecule API Manufacturing
    • 3.15.6 Expanding through New Services
    • 3.15.7 Boehringer Ingelheim Biopharmaceuticals: Opportunities for Growth
  • 3.16 Catalent Pharma Solutions - the World's Leading CMO
    • 3.16.1 Catalent: Manufacturing Services and Capabilities
    • 3.16.2 Divisional Segmentation -Catalent's Service
    • 3.16.3 Catalent Pharma's Revenue Growth, 2012-2017
    • 3.16.4 Catalent Is Expanding its Soft Gel Technologies Division
    • 3.16.5 Quadrupling Biopharmaceutical Manufacturing Capacity
    • 3.16.6 Expansion of Packaging Services in Asia-Pacific and Europe: 2015
    • 3.16.7 Adding New Early-Stage Development Services
    • 3.16.8 Expansion in Japan - Growth Prospects for Catalent
    • 3.16.9 New Business Contracts 2014-2016
    • 3.16.10 Catalent: Opportunities for Growth
  • 3.17 Charles River Laboratories International, Inc.
    • 3.17.1 Charles River Laboratories Focuses on Increasing the Service Areas of its Offerings
    • 3.17.2 Strategic Acquisitions as a Growth Strategy to Expand Product Portfolio
    • 3.17.3 Charles River Laboratories Revenue Growth, 2012-2017
  • 3.18 Cardinal Health, Inc.
    • 3.18.1 Cardinal Health Focuses on Helping Healthcare Organizations for Patient Safety
    • 3.18.2 Cardinal Revenue Growth, 2012-2017
  • 3.19 CordenPharma International
    • 3.19.1 CordenPharma Service Division
    • 3.19.2 CordenPharma Emerging in the API Market
    • 3.19.3 Investments in Highly Potent Capabilities
    • 3.19.4 CordenPharma: SWOT Analysis
  • 3.20 Daito Pharmaceutical Co., Ltd.
    • 3.20.1 Daito Has a Portfolio of More than 43 APIs
    • 3.20.2 Rapid Growth in Revenue and Operational Profit: Daito Financial Performance 2012-2017
    • 3.20.3 Daito Is Well-Placed for Asian Market Growth - SWOT Analysis
  • 3.21 Delpharm
    • 3.21.1 Finished Dosage Form Manufacturing for Developed Markets
    • 3.21.2 Delpharm: Rapid Revenue Growth Via Acquisitions, 2012-2017
    • 3.21.3 Delpharm: Outlook and Prospects for Growth
  • 3.22 Divis Laboratories
    • 3.22.1 Divis Laboratories and the Contract Manufacturing Industry
    • 3.22.2 Divis Laboratories: A Rapidly Growing CMO, 2012-2017
    • 3.22.3 Divis Laboratories: API Manufacturing
  • 3.23 Dr. Reddy's Laboratories Ltd.
    • 3.23.1 API and FDF Manufacturing Services
    • 3.23.2 Dr. Reddy's PSAI: Strong Revenue Growth 2012-2017
    • 3.23.3 Advancing in Complex Drug Manufacturing
    • 3.23.4 Expanding in the European Manufacturing Market
  • 3.24 DPT Laboratories, Ltd.
    • 3.24.1 Mylan Acquires Topicals-Focused Specialty and Generic Business of DPT
    • 3.24.2 DPT Enhances Flexibility and Efficiencies
    • 3.24.3 DPT Enhances Capabilities with New High-Speed Filling Center
  • 3.25 Esteve Qu`mica
    • 3.25.1 Esteve Química Manufactures APIs for Developed and Emerging Markets
    • 3.25.2 Expanding in the US, 2016
    • 3.25.3 Esteve Química: SWOT Analysis
  • 3.26 Evonik Degussa
    • 3.26.1 Investing in API and Drug Delivery Services
    • 3.26.2 Moderate Growth in Pharmaceutical Manufacturing Services, 2012-2017
    • 3.26.3 Evonik Is a HPAPI Specialist
    • 3.26.4 Evonik Continues to Grow Across All Segments
    • 3.26.5 How Can Evonik Expand in the Pharmaceutical Contract Manufacturing Market?
  • 3.27 FAMAR Health Care Services
    • 3.27.1 Famar Is an Expert in Lyophilisation
    • 3.27.2 Sustained Growth in Famar's Revenue: 2011-2016
    • 3.27.3 Expanding Outside Europe
    • 3.27.4 Further Site Acquisitions Are an Opportunity for Growth
  • 3.28 Fareva Group
    • 3.28.1 Fareva Has 35 Years' Manufacturing Experience
    • 3.28.2 Revenue Growth through Acquisitions: 2012-2017
    • 3.28.3 Fareva SWOT Analysis
  • 3.29 FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
    • 3.29.1 Opening of New Manufacturing facility
    • 3.29.2 Fujifilm Establishes Cell Culture Process Development Laboratories
    • 3.29.3 Fujifilm Completes Acquisition of Kalon Biotherapeutics LLC
  • 3.30 GlaxoSmithKline plc
    • 3.30.1 GSK Enters into an Agreement with Novartis for Full Ownership of Consumer Healthcare Business
    • 3.30.2 GSK Received Complete Response from FDA for Candidate Pandemic H5N1 Adjuvanted Influenza Vaccine
  • 3.31 Pfizer CentreOne
    • 3.31.1 Pfizer CentreSource: Historic Revenue Performance, 2012-2017
    • 3.31.2 Will Hospira Acquisition Lead to Revenue Growth in Future?
  • 3.32 Huapont Pharmaceutical Co., Ltd.
    • 3.32.1 China Pharmaceutical Trade
  • 3.33 Lonza
    • 3.33.1 Lonza Is a Leader in Biologics Manufacturing
    • 3.33.2 Lonza Contract Manufacturing and Development: 2012-2017
    • 3.33.3 Investing in Advanced Biological Drug Sectors
    • 3.33.4 The Promise of Antibody-Drug Conjugates (ADCs)
    • 3.33.5 The Regenerative Medicine Future in Japan
    • 3.33.6 Lonza: SWOT Analysis
  • 3.34 Nipro Corporation: Japan's Leading CMO
    • 3.34.1 Nipro Pharmaceutical Contract Manufacturing Capabilities
    • 3.34.2 Nipro Revenues 2012-2017
    • 3.34.3 Biosimilars and Anti-Cancer Drugs Are Opportunities for Future Growth: SWOT Analysis
  • 3.35 Paragon Bioservices, Inc.
    • 3.35.1 Paragon Announced Expansion of its New Manufacturing Facility
  • 3.36 Patheon - One of the Top 3 CMOs
    • 3.36.1 Patheon - Global leader in Pharmaceutical Development Services
    • 3.36.2 Contract Manufacturing Services at Patheon
    • 3.36.3 Steady Revenue Growth 2012-2017
    • 3.36.4 DPx Holdings: Developments
    • 3.36.5 Adding New Formulations and Formulation Development Services
    • 3.36.6 Expanding Services Through Acquisition, 2016
    • 3.36.7 Patheon: SWOT Analysis
  • 3.37 Recipharm
    • 3.37.1 Contract Development and Manufacturing Services
    • 3.37.2 Recipharm: Financial Performance 2012-2017
    • 3.37.3 Recipharm Invests in Facility Expansion
    • 3.37.4 Recipharm Growing in the Development and Technology Market Through Acquisitions
    • 3.37.5 Recipharm: SWOT Analysis
  • 3.38 F. Hoffman-La Roche Ltd.
    • 3.38.1 Amplified Revenue Growth in Pharma Manufacturing 2012-2017
    • 3.38.2 Value of Innovation
    • 3.38.3 Approvals and Extensions in Pharmaceuticals Division
    • 3.38.4 Launch of New Products Drive the Growth of the Company
  • 3.39 Royal DSM
    • 3.39.1 Amplified Revenue Growth in Pharma Manufacturing 2012-2017
    • 3.39.2 DSM Pharmaceuticals Products/DPx Holdings: Manufacturing Services
    • 3.39.3 DSM Sinochem Pharmaceuticals: A World Leader in Antibacterial Manufacturing
    • 3.39.4 DPx Holdings: A New Pharma Leader
    • 3.39.5 Investing in Biopharma Manufacturing
    • 3.39.6 Expanding API Manufacturing
    • 3.39.7 Generics and Biologics Offer Room for Growth
  • 3.40 Shandong Xinhua Pharmaceutical
    • 3.40.1 Experience in APIs and Finished Dosage Forms
    • 3.40.2 Shandong Xinhua: Strong Revenue Growth 2012-2017
    • 3.40.3 Growing through Joint Ventures
    • 3.40.4 Looking to Expand in the US and EU
  • 3.41 Siegfried
    • 3.41.1 Siegfried's Acquisitions, 2012-2017
    • 3.41.2 Expanding Siegfried's Manufacturing Footprint Globally
    • 3.41.3 Expanding High Potency API Capabilities
    • 3.41.4 Siegfried: Financial Performance 2012-2017
    • 3.41.5 Siegfried's Characteristics within the Contract Manufacturing Market: SWOT Analysis
  • 3.42 TEVA Pharmaceutical, Ltd.
    • 3.42.1 API Manufacturing Services
    • 3.42.2 Teva API: Financial Performance 2012-2017
    • 3.42.3 Building a Footprint in Mexico, India and China
    • 3.42.4 Teva API: SWOT Analysis
  • 3.43 Therapure Biopharma, Inc.
    • 3.43.1 Therapure Collaborated with 3SBio Inc., and CPE Funds
  • 3.44 UPM Pharmaceuticals
  • 3.45 Vetter Pharmaceutical
    • 3.45.1 Vetter is an Injectable Manufacturing Specialist
    • 3.45.2 Services, Collaborations and Differentiating Factors
    • 3.45.3 Expanding Services in the US and Asia
    • 3.45.4 Biologics: Opportunity for Growth for Vetter
  • 3.46 Xcelience, LLC
  • 3.47 Xcellerex, Inc.
  • 3.48 Piramal Pharma Solutions
    • 3.48.1 Mergers and Acquisitions
    • 3.48.2 Piramal Pharma Solutions: Financial Performance 2012-2017
    • 3.48.3 Investment in Technology-based Delivery Platforms
    • 3.48.4 Quality Governance
  • 3.49 Zhejiang Hisun Pharmaceutical
    • 3.49.1 API Manufacturing for Markets Worldwide
    • 3.49.2 Moving into International Drug Marketing
    • 3.49.3 Zhejiang Hisun: Opportunities for Growth
  • 3.50 Zhejiang Huahai Pharmaceuticals
    • 3.50.1 Zhejiang Huahai is a Market Leader Within the Antihypertensive API Market
    • 3.50.2 Zhejiang Huahai: Contract Manufacturing Performance 2012-2017
    • 3.50.3 Expanding in the US Generic Drugs Market
    • 3.50.4 Zhejiang Huahai: SWOT Analysis

4. Conclusions of the Study

  • 4.1 What Has Driven Growth for CMO Market Leaders in Recent Years?
  • 4.2 Strategies for Growth: Prospects for Leading CMOs
  • 4.3 High Demand for Biopharmaceutical Manufacturing Services
  • 4.4 Investing in Novel Technologies
  • 4.5 Outlook for API Manufacturers

Appendices

  • Some Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form

List of Tables

  • Table 2.1 Benefits and Drawbacks to Outsourcing Pharmaceutical Manufacturing, 2017
  • Table 2.2 Contract Manufacturing Market Total Revenue: Total Revenue ($bn), Annual Growth (%), 2015-2017
  • Table 2.3 Contract Manufacturing Market by Leading Country: Market Size ($bn), Market Share (%), 2017
  • Table 3.1 Alcami Details, 2017
  • Table 3.2 Alcami Facility Details, 2017
  • Table 3.3 AbbVie Contract Manufacturing: Details, 2017
  • Table 3.4 AbbVie Contract Manufacturing Facility Capabilities, 2017
  • Table 3.5 AbbVie Contract Manufacturing SWOT Analysis, 2017
  • Table 3.6 Aenova Group Details, 2017
  • Table 3.7 Aenova Group Manufacturing Capacity by Dosage Form, 2017
  • Table 3.8 Aenova Group Manufacturing Facility Details, 2017
  • Table 3.9 Aenova Group SWOT Analysis, 2017
  • Table 3.10 Aesica Details, 2017
  • Table 3.11 Aesica Pharmaceuticals: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2012-2017
  • Table 3.12 Aesica SWOT Analysis, 2018
  • Table 3.13 Ajinomoto Althea, Inc. Details, 2017
  • Table 3.14 Albany Molecular Research, Inc. Details, 2017
  • Table 3.15 Alkermes Details, 2017
  • Table 3.16 Almac Details, 2017
  • Table 3.17 Almac Pharmaceutical Manufacturing Facilities Details, 2017
  • Table 3.18 Almac: SWOT Analysis, 2017
  • Table 3.19 Amatsigroup Details, 2017
  • Table 3.20 Aurobindo Pharma Details, 2016
  • Table 3.21 Aurobindo Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2012-2017
  • Table 3.22 Aurobindo Contract Manufacturing: SWOT Analysis, 2017
  • Table 3.23 Avid Bioservices, Inc. Details, 2017
  • Table 3.24 Bayer Healthcare AG Details, 2017
  • Table 3.25 Baxter BioPharma Solutions Details, 2017
  • Table 3.26 Baxter BioPharma Solutions: Facilities and Services Offered, 2016
  • Table 3.27 Baxter BioPharma Solutions SWOT Analysis, 2017
  • Table 3.28 Biomay AG Details, 2017
  • Table 3.29 Boehringer Ingelheim Biopharmaceuticals Details, 2017
  • Table 3.30 Boehringer Ingelheim Total Pharmaceutical Manufacturing Capacity: Reactor Size and Number of Units by CMO Service, 2017
  • Table 3.31 Products Developed by Boehringer Ingelheim Biopharmaceuticals, 1983-2014
  • Table 3.32 Boehringer Ingelheim Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2012-2017
  • Table 3.33 Boehringer Ingelheim: SWOT Analysis, 2017
  • Table 3.34 Catalent Details, 2017
  • Table 3.35 Catalent Facility Details, 2017
  • Table 3.36 Catalent Financial Performance: Revenue ($m), Annual Growth Rates (%), CAGR (%), 2012-2017
  • Table 3.37 Catalent Financial Performance by Product Type: Revenue ($m), Revenue Share (%), 2017
  • Table 3.38 Catalent Pharma SWOT Analysis, 2017
  • Table 3.39 Charles River Laboratories International, Inc. Details, 2017
  • Table 3.40 Charles River Financial Performance: Revenue ($m), Annual Growth Rates (%), CAGR (%), 2012-2017
  • Table 3.41 Cardinal Health, Inc. Details, 2017
  • Table 3.42 Cardinal Health Financial Performance: Revenue ($b), Annual Growth Rates (%), CAGR (%), 2012-2017
  • Table 3.43 CordenPharma International Details, 2017
  • Table 3.44 CordenPharma Facilities and Service Details, 2017
  • Table 3.45 CordenPharma SWOT Analysis, 2017
  • Table 3.46 Daito Pharmaceutical: Details, 2017
  • Table 3.47 Daito Pharmaceuticals Financial Performance: Revenue ($m), Revenue (¥m), CAGR (%), 2012-2017
  • Table 3.48 Daito Pharmaceuticals SWOT Analysis, 2017
  • Table 3.49 Delpharm Details, 2017
  • Table 3.50 Delpharm: Facilities and Services, 2017
  • Table 3.51 Delpharm: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2012-2017
  • Table 3.52 Delpharm: SWOT Analysis, 2017
  • Table 3.53 Divis Laboratories Details, 2017
  • Table 3.54 Divis Laboratories: Facility Details, Production Capacity and Services, 2017
  • Table 3.55 Divis Laboratories: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2012-2017
  • Table 3.56 Divis Laboratories Revenue Distribution: Revenue ($m), Share of Total (%), 2017
  • Table 3.57 Divis Laboratories Revenue by Region: Revenue ($m), Share of Total (%), 2017
  • Table 3.58 Divis Laboratories Contract Manufacturing: SWOT Analysis, 2017
  • Table 3.59 Dr. Reddy's Laboratories Ltd. Details, 2017
  • Table 3.60 Dr. Reddy's Laboratories Cumulative Drug Master File (DMF) Applications: Applications Accepted by Region, Regional Share (%), 2017
  • Table 3.61 Dr. Reddy's Laboratories Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2012-2017
  • Table 3.62 Dr. Reddy's Laboratories: Contract Manufacturing Revenue ($m) by Regional Market and Revenue Share (%), FY 2017
  • Table 3.63 Dr. Reddy's Laboratories: SWOT Analysis, 2017
  • Table 3.64 DPT Laboratories Ltd. Details, 2017
  • Table 3.65 Esteve Química Details, 2017
  • Table 3.66 Esteve Química SWOT Analysis, 2017
  • Table 3.67 Evonik Degussa Details, 2017
  • Table 3.68 Evonik Health and Nutrition: R&D and Production Sites by Region, 2017
  • Table 3.69 Evonik Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2012-2017
  • Table 3.70 Evonik Pharmaceutical Manufacturing: SWOT Analysis, 2017
  • Table 3.71 Famar Details, 2017
  • Table 3.72 Famar Pharmaceutical Manufacturing Facilities, 2017
  • Table 3.73 Famar Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2011-2016
  • Table 3.74 Famar: SWOT Analysis, 2017
  • Table 3.75 Fareva Details, 2016
  • Table 3.76 Fareva Manufacturing Facilities, 2017
  • Table 3.77 Fareva Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2012-2017
  • Table 3.78 Fareva: SWOT Analysis, 2017
  • Table 3.79 FUJIFILM Diosynth Biotechnologies U.S.A., Inc. Details, 2017
  • Table 3.80 GlaxoSmithKline plc Details, 2017
  • Table 3.81 Pfizer CentreOne Details, 2017
  • Table 3.82 Pfizer CentreSource: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2012-2017
  • Table 3.83 Pfizer CentreOne SWOT Analysis, 2017
  • Table 3.84 Huapont Pharmaceutical Co., Ltd. Details, 2017
  • Table 3.85 Lonza Details, 2017
  • Table 3.86 Selected Lonza Pharmaceutical and Biotech Manufacturing and Development Agreements, 2010-2015
  • Table 3.87 Lonza Pharma & Biotech Department: Revenue ($m), 2012-2018
  • Table 3.88 ADCs Approved and in Late Stage Clinical Development, 2014
  • Table 3.89 Lonza SWOT Analysis, 2017
  • Table 3.90 Nipro Pharma Details, 2017
  • Table 3.91 Nipro Pharmaceutical Contract Manufacturing Capabilities: 2012-2017
  • Table 3.92 Nipro Pharmaceutical Contract Manufacturing: Annual Production Capacity, 2017
  • Table 3.93 Nipro Pharmaceutical Contract Manufacturing Financial Performance: Revenue ($m), Annual Growth Rates (%), CAGR (%), 2012-2017
  • Table 3.94 Nipro Pharmaceutical Contract Manufacturing SWOT Analysis, 2017
  • Table 3.95 Paragon Bioservices, Inc. Details, 2017
  • Table 3.96 Patheon Details, 2017
  • Table 3.97 Patheon Manufacturing Facilities, 2017
  • Table 3.98 Patheon Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rates (%), CAGRs (%), 2012-2017
  • Table 3.99 Patheon: SWOT Analysis, 2017
  • Table 3.100 Recipharm Details, 2017
  • Table 3.101 Recipharm: Facility Details and Services, 2017
  • Table 3.102 Recipharm: Revenue ($m), Annual Growth Rates (%), CAGRs (%), 2012-2017
  • Table 3.103 Recipharm Manufacturing Revenue by Client Size: Revenue ($m), Share of Total Revenues (%), 2017
  • Table 3.104 Recipharm Manufacturing Revenue Distribution: Customer Revenue ($m), Share of Total Revenues (%), 2017
  • Table 3.105 Recipharm: SWOT Analysis, 2017
  • Table 3.106 F. Hoffman-La Roche Details, 2017
  • Table 3.107 Roche Pharmaceutical Manufacturing: Revenue ($bn), Annual Growth (%), CAGR (%) 2012-2017
  • Table 3.108 Royal DSM Details, 2017
  • Table 3.109 Royal DSM Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%) 2012-2017
  • Table 3.110 DSM Pharmaceutical Products (DPP)/DPx Holdings Division: Revenue ($m), Annual Growth (%), CAGR (%), 2011-2016
  • Table 3.111 DSM Sinochem Pharmaceuticals (DSP): Revenue ($m), Annual Growth (%), CAGR (%), 2012-2017
  • Table 3.112 DSM Pharmaceutical Manufacturing: SWOT Analysis, 2017
  • Table 3.113 Shandong Xinhua Pharmaceuticals Details, 2017
  • Table 3.114 Shandong Xinhua Pharmaceutical Production Capacity by Dosage Form, 2017
  • Table 3.115 Shandong Xinhua: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2012-2017
  • Table 3.116 Shandong Xinhua Revenue Share by Geographic Region: Revenue Share (%), 2017
  • Table 3.117 Shandong Xinhua Manufacturing: SWOT Analysis, 2017
  • Table 3.118 Siegfried Details, 2017
  • Table 3.119 Siegfried Pharmaceutical Manufacturing Facilities Details, 2017
  • Table 3.120 Siegfried Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rates (%), CAGRs (%), 2012-2017
  • Table 3.121Siegfried: SWOT Analysis, 2017
  • Table 3.122 Teva API Details, 2017
  • Table 3.123 Teva API: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2012-2017
  • Table 3.124 Teva API SWOT Analysis, 2017
  • Table 3.125 Therapure Biopharma Details, 2017
  • Table 3.126 UPM Pharmaceuticals Details, 2017
  • Table 3.127 Vetter Details, 2017
  • Table 3.128 Vetter Pharmaceutical Facilities, 2017
  • Table 3.129 Vetter: SWOT Analysis, 2017
  • Table 3.130 Xcelience LLC Details, 2017
  • Table 3.131 Xcellerex, Inc. Details, 2017
  • Table 3.132 Piramal Pharma Solutions Details, 2017
  • Table 3.133 Piramal Pharma Solutions: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2012-2017
  • Table 3.134 Zhejiang Hisun Pharmaceuticals Details, 2017
  • Table 3.135 Zhejiang Hisun Manufacturing: SWOT Analysis, 2017
  • Table 3.136 Zhejiang Huahai Pharmaceuticals Details, 2017
  • Table 3.137 Zhejiang Huahai Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2012-2017
  • Table 3.138 Zhejiang Huahai Contract Manufacturing: SWOT Analysis, 2017
  • Table 4.1 Top Five Developed and Emerging Market CMOs: Grouped Revenue ($m), Annual Growth Rate (%), CAGR (%), 2012-2017

List of Figures

  • Figure 2.1 Selected Services Contracted to CMOs by Developmental Stage, 2017
  • Figure 2.2 Contract Manufacturing Market Total Revenue: Total Revenue ($bn), 2015-2017
  • Figure 2.3 Contract Manufacturing Market by Leading Country: Market Share (%), 2017
  • Figure 2.4 Pharmaceutical Contract Manufacturing: Drivers and Restraints
  • Figure 3.1 Aesica Pharmaceuticals: Revenue ($m), 2012-2017
  • Figure 3.2 Aurobindo Contract Manufacturing: Revenue ($m), 2012-2017
  • Figure 3.3 Boehringer Ingelheim Pharmaceutical Manufacturing: Revenue ($m), 2012-2017
  • Figure 3.4 Catalent Facilities by Region, 2017
  • Figure 3.5 Catalent Facilities by Service Offered, 2017
  • Figure 3.6 Catalent Financial Performance: Revenue ($m), 2012-2017
  • Figure 3.7 Catalent Financial Performance by Product Type: Revenue Share (%), 2017
  • Figure 3.7 Charles River Laboratories Financial Performance: Revenue ($m), 2012-2017
  • Figure 3.8 Cardinal Health Financial Performance: Revenue ($b), 2012-2017
  • Figure 3.9 Daito Pharmaceuticals Financial Performance: Revenue ($m), 2012-2017
  • Figure 3.10 Delpharm: Revenue ($m), 2012-2017
  • Figure 3.11 Divis Laboratories Contract Manufacturing: Revenue ($m), 2012-2017
  • Figure 3.12 Divis Laboratories Revenue Distribution: Revenue ($m), 2017
  • Figure 3.13 Divis Laboratories Revenue by Region: Share of Total (%), 2017
  • Figure 3.14 Dr. Reddy's Laboratories Cumulative Drug Master File (DMF) Applications: Accepted by Region (%), 2017
  • Figure 3.15 Dr. Reddy's Laboratories Contract Manufacturing: Revenue ($m), 2012-2017
  • Figure 3.16 Dr. Reddy's Laboratories Contract Manufacturing Revenue: Regional Revenue Share (%), FY 2017
  • Figure 3.17 Evonik Health and Nutrition: R&D and Production Sites (%) by Region, 2017
  • Figure 3.18 Evonik Pharmaceutical Manufacturing: Revenue ($m), 2012-2017
  • Figure 3.19 Famar Pharmaceutical Manufacturing: Revenue ($m), 2011-2016
  • Figure 3.20 Fareva Pharmaceutical Manufacturing: Revenue ($m), 2012-2017
  • Figure 3.21 Pfizer CentreOne: Revenue ($m), 2012-2017
  • Figure 3.22 Lonza Pharma & Biotech: Revenue ($m), 2012-2018
  • Figure 3.23 Lonza Custom Manufacturing by Regional Market: Revenue Share (%), 2017
  • Figure 3.24 Nipro Pharmaceutical Contract Manufacturing Capabilities: Orally Administered Drugs, Injectables, External Preparations, 2012-2017
  • Figure 3.25 Nipro Pharmaceuticals Financial Performance: Revenue ($m), 2012-2017
  • Figure 3.26 Patheon Pharmaceutical Development Projects (%) by Phase, 2017
  • Figure 3.27 Patheon Pharmaceutical Manufacturing Projects by Client Size: Proportion of Total Revenue (%), 2017
  • Figure 3.28 Patheon Pharmaceutical Manufacturing: Revenue ($m), 2012-2017
  • Figure 3.29 Recipharm: Revenue ($m), 2012-2017
  • Figure 3.30 Recipharm Manufacturing Revenue by Client: Share of Total Revenues (%), 2017
  • Figure 3.31 Recipharm Manufacturing Revenue Distribution: Customer Revenue ($m), 2017
  • Figure 3.32 Roche Pharmaceutical Manufacturing: Revenue ($b), 2012-2017
  • Figure 3.33 Royal DSM Pharmaceutical Manufacturing: Revenue ($m), 2012-2017
  • Figure 3.34 DSM Pharmaceutical Products (DPP)/ DPx Holdings Division: Revenue ($m), 2011-2016
  • Figure 3.35 DSM Sinochem Pharmaceuticals (DSP): Revenue ($m), 2012-2017
  • Figure 3.36 Shandong Xinhua: Revenue ($m), 2012-2017
  • Figure 3.37 Shandong Xinhua Revenue Share by Geographic Region: Revenue Share (%), 1H 2017
  • Figure 3.38 Siegfried Pharmaceutical Manufacturing: Revenue ($m), 2012-2017
  • Figure 3.39 Teva API: Revenue ($m), 2012-2017
  • Figure 3.40 Piramal Pharma Solutions: Revenue ($m), 2012-2017
  • Figure 3.41 Zhejiang Huahai Contract Manufacturing: Revenue ($m), 2012-2017
  • Figure 4.1 Top Five Developed and Emerging Market CMOs: Grouped Revenue ($m), 2012-2017

companies listed

  • 3SBio Inc.
  • Abbott
  • AbbVie
  • Accucaps Industries Limited
  • Acorda
  • Activa Capital
  • Acumen Pharmaceuticals, Inc.
  • AdAlta
  • Adamas Pharmaceuticals
  • Aenova Group
  • Aesica Pharmaceuticals
  • Agennix
  • Agere Pharmaceuticals
  • Ajinomoto Althea, Inc.
  • Albany Molecular Research, Inc.
  • Alcami Corporation
  • Alkermes plc
  • Alliance Medical Products (AMP)
  • Almac Group
  • Althea Technologies Inc.
  • Amatsigroup
  • AmatsiQBiologicals
  • AMYRA Biotech
  • Apexigen
  • arGEN-X
  • Astellas Pharma
  • AstraZeneca
  • Athera Biotechnologies
  • Aurobindo Pharma Ltd.
  • Avalanche Biotechnologies
  • Avepharm
  • Avid Bioservices Inc.
  • Avogadro
  • Banner Life Sciences
  • Baxter Biopharma Solutions
  • Bayer AG
  • BC Partners
  • Biogen
  • Biomay AG
  • Bionomics
  • Biotest
  • Boehringer Ingelheim BioXcellence
  • Boehringer Ingelheim GmbH
  • Breckenridge Pharmaceutical
  • Bristol-Myers Squibb
  • Cambridge Major Laboratories, Inc.
  • Carbogen Amcis
  • Cardinal Health
  • Catalent Pharma Solutions Inc.
  • Catalyst Capital Group, Inc.
  • Celladon
  • Celldex Therapeutics
  • Celsion
  • CEVEC Pharmaceuticals
  • Charles River Laboratories International Inc.
  • Chemisch-Pharmazeutisches Laboratorium Ravensburg
  • Chemtrix
  • Chongqing Huapont Pharmaceutical Co., Ltd.
  • Circadian Technologies
  • CITICPE
  • Cleveland BioLabs
  • Cobra Biomanufacturing
  • Consort Medical
  • Corden Pharmaceutical
  • Corvette
  • CPE Funds
  • Daiichi Sankyo
  • Daito Pharmaceutical
  • DBI
  • Delmas Perfusion
  • Delpharm
  • Divis Laboratories Ltd.
  • DPT Laboratories
  • DPX Holdings
  • Dr. Reddy's Laboratories Ltd.
  • Dragenopharm Apotheker Püschl
  • DSM Pharmaceutical Products (DPP)
  • Eagle Pharmaceuticals
  • Eclipse Therapeutics
  • Eisai
  • Ekkio Capital
  • Eli Lilly
  • EmulTech
  • Enzon Pharmaceuticals
  • Esteve Química
  • Euro Vital Pharma
  • Eurofins Amatsigroup
  • Euticals
  • Evonik
  • Exelixis
  • Famar Health Care Services
  • Fareva
  • Flamel Technologies
  • Frazier Healthcare
  • Fujifilm Diosynth Biotechnologies UK Ltd.
  • Gadea Pharmaceutical Group
  • Gallus BioPharmaceuticals
  • Genzyme
  • GlaxoSmithKline (GSK)
  • Hameln Pharmaceuticals GmbH
  • Hameln RDS GmbH
  • Haupt Pharma
  • Hospira, Inc.
  • Huapont Medical
  • Human Genome Sciences
  • Icagen, Inc.
  • Immune Pharmaceuticals
  • Immunomedics
  • Index Ventures
  • Indoco Remedies
  • Intellect Neurosciences
  • International Chemical Investors Group (ICIG)
  • IRIX Pharmaceuticals
  • Janssen
  • JK Pharmaceutical
  • JLL Partners
  • Johnson & Johnson (J&J)
  • KWS BioTest Limited
  • Laboratoire Aguettant
  • Laboratoires Besins
  • Lanxess Corporation
  • Lonza Group Ltd.
  • Lusomedicamenta
  • Madison Dearborn Partners, LLC (MDP)
  • Marine Ingredients
  • Marinopoulos Group
  • Merck KGaA
  • Mesoblast
  • Micron Technologies
  • Molecular Partners
  • Mundipharma
  • Mylan
  • New York Center for Nanomedicine Research (NYCNMR)
  • NIH CRM
  • Nikon
  • Nipro Corporation
  • Novozymes
  • Octane
  • OncoMed Pharmaceuticals
  • OPKO Health. Inc.
  • Opthea
  • Orpegen Peptide Chemicals GmbH
  • Osiris Therapeutics
  • Paragon Bioservices Inc
  • Patheon Inc
  • Pfizer
  • Pfizer CentreOne
  • Pfizer Inc./Pfizer CentreSource (PCS)
  • Pharmacia (now Pfizer)
  • Pharmacyclis
  • Pharmatek Laboratories, Inc.
  • Piramal
  • Piramal Healthcare L
  • Precision Ocular Ltd
  • Prime European Therapeuticals S.p.A
  • Progenics Pharmaceuticals
  • Propanc Health Group
  • Q-Biologicals
  • R5 Pharmaceuticals
  • Ranbaxy
  • Recipharm A
  • Regeneus
  • Relthy Laboratórios
  • Relypsa
  • Renaissance Acquisition Holdings, LLC
  • Rexim
  • Roche
  • Royal DSM
  • Sandoz
  • Sanofi
  • Schering (now Bayer)
  • Seattle Genetics
  • Sentry BioPharma Services
  • Servier
  • Shandong Tianda Biological Pharmaceutical
  • Shandong Xinhua Pharmaceutical
  • Siegfried
  • Sigma-Aldrich
  • Sigmar Italia
  • Sinopharm
  • Solasia Pharma
  • Solvay
  • SurModics
  • Swedish Orphan Biovitrium AB (Sobi)
  • Swiss Caps
  • Syntex (now Roche)
  • Takeda
  • Temmler Group
  • Tessenderlo Group
  • Teva
  • The Carlyle Group
  • Therapure Biopharma Inc.
  • TL Biopharmaceuticals Ltd
  • Tohoku Nipro Pharmaceutical Corporation
  • Tunitas Therapeutics
  • UCB
  • UMN Pharma
  • UPM Pharmaceuticals Inc.
  • Valerion Therapeutics
  • Vetter Pharmacuticals
  • Virbac
  • Whitehouse Analytical Laboratories, LLC.
  • WindRose
  • Xcelience LLC
  • Xcellerex LLC
  • Xinhua Pharmaceutical (Gaomi) Company
  • XOMA
  • Yiwu Huayi Fine Chemical Co.
  • Zhejiang Hisun Pharmaceutical
  • Zhejiang Huahai Pharmaceuticals
  • Zhejiang Jiang Yuan Tang
  • Zumutor
  • ZYMtronix

List of Organizations Mentioned in the Report

  • Agence Nationale de sécurité du Médicament et des produits de santé (ANSM)
  • Agência Nacional de Vigiláncia Sanitária (ANVISA)
  • Biomedical Advanced Research and Development Authority (BARDA)
  • Cardinal Health Foundation
  • Eindhoven University of Technology
  • FDA
  • Générique Même Médicament (GEMME)
  • Health Canada
  • International Chemical Investors Group (ICIG)
  • MHRA
  • Queens University Belfast
  • Sanquin Blood Supply Foundation
  • University College London (UCL)
  • University of Bradford
  • University of Durham
  • University of Leeds
Back to Top
전화 문의
F A Q